Amgen’s (AMGN) “Buy” Rating Reaffirmed at Cowen

Cowen reissued their buy rating on shares of Amgen (NASDAQ:AMGN) in a report published on Friday. They currently have a $204.00 price objective on the medical research company’s stock.

Other analysts have also issued research reports about the company. Cann reissued a buy rating and set a $203.00 price target on shares of Amgen in a report on Friday, October 6th. Bank of America boosted their price objective on Amgen to $210.00 and gave the company a buy rating in a research report on Thursday, October 5th. Oppenheimer restated a buy rating and issued a $203.00 price objective on shares of Amgen in a research report on Friday, October 6th. Mizuho restated a buy rating and issued a $198.00 price objective on shares of Amgen in a research report on Friday, October 6th. Finally, Zacks Investment Research upgraded Amgen from a hold rating to a buy rating and set a $199.00 price objective on the stock in a research report on Friday, October 27th. Sixteen equities research analysts have rated the stock with a hold rating and eleven have issued a buy rating to the stock. The stock currently has an average rating of Hold and an average price target of $191.49.

Shares of Amgen (NASDAQ AMGN) opened at $174.75 on Friday. Amgen has a fifty-two week low of $152.16 and a fifty-two week high of $201.23. The company has a current ratio of 5.49, a quick ratio of 5.17 and a debt-to-equity ratio of 1.35. The stock has a market capitalization of $126,850.00, a PE ratio of 67.73, a price-to-earnings-growth ratio of 2.69 and a beta of 1.42.

Amgen (NASDAQ:AMGN) last released its quarterly earnings results on Thursday, February 1st. The medical research company reported $2.89 earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of $3.03 by ($0.14). Amgen had a net margin of 8.66% and a return on equity of 30.87%. The company had revenue of $5.80 billion for the quarter, compared to the consensus estimate of $5.84 billion. During the same period in the prior year, the firm posted $2.89 EPS. The business’s revenue for the quarter was down 2.7% on a year-over-year basis. equities research analysts expect that Amgen will post 12.96 EPS for the current fiscal year.

The company also recently announced a quarterly dividend, which will be paid on Thursday, March 8th. Investors of record on Thursday, February 15th will be given a $1.32 dividend. This is an increase from Amgen’s previous quarterly dividend of $1.15. This represents a $5.28 dividend on an annualized basis and a dividend yield of 3.02%. The ex-dividend date is Wednesday, February 14th. Amgen’s payout ratio is currently 178.29%.

Amgen announced that its board has approved a share repurchase program on Wednesday, October 25th that permits the company to repurchase $5.00 billion in outstanding shares. This repurchase authorization permits the medical research company to repurchase shares of its stock through open market purchases. Stock repurchase programs are usually a sign that the company’s management believes its shares are undervalued.

In other Amgen news, EVP Sean E. Harper sold 1,525 shares of the company’s stock in a transaction that occurred on Tuesday, January 16th. The stock was sold at an average price of $185.62, for a total transaction of $283,070.50. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, Director Carbonnel Francois De sold 4,000 shares of the company’s stock in a transaction that occurred on Wednesday, November 8th. The shares were sold at an average price of $173.61, for a total value of $694,440.00. The disclosure for this sale can be found here. Insiders sold 8,575 shares of company stock worth $1,508,836 over the last quarter. 0.19% of the stock is owned by company insiders.

Hedge funds have recently modified their holdings of the business. Welch Group LLC purchased a new stake in Amgen during the second quarter valued at approximately $639,000. DekaBank Deutsche Girozentrale raised its position in Amgen by 2.8% during the second quarter. DekaBank Deutsche Girozentrale now owns 883,579 shares of the medical research company’s stock valued at $152,927,000 after purchasing an additional 24,219 shares during the period. Pacer Advisors Inc. raised its position in Amgen by 10.3% during the second quarter. Pacer Advisors Inc. now owns 25,378 shares of the medical research company’s stock valued at $4,371,000 after purchasing an additional 2,362 shares during the period. Wesbanco Bank Inc. raised its position in Amgen by 6.5% during the second quarter. Wesbanco Bank Inc. now owns 106,792 shares of the medical research company’s stock valued at $18,393,000 after purchasing an additional 6,492 shares during the period. Finally, Coho Partners Ltd. raised its position in Amgen by 25.8% during the second quarter. Coho Partners Ltd. now owns 1,034,651 shares of the medical research company’s stock valued at $178,198,000 after purchasing an additional 212,213 shares during the period. Institutional investors and hedge funds own 78.59% of the company’s stock.

COPYRIGHT VIOLATION WARNING: This piece of content was published by Stock Observer and is owned by of Stock Observer. If you are viewing this piece of content on another domain, it was stolen and republished in violation of U.S. & international trademark and copyright legislation. The original version of this piece of content can be accessed at https://www.thestockobserver.com/2018/02/06/amgens-amgn-buy-rating-reaffirmed-at-cowen.html.

About Amgen

Amgen Inc is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine).

Analyst Recommendations for Amgen (NASDAQ:AMGN)

Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply